Disparities in access to anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration
Robert P Finger, Jing Xie, Kathy Fotis, Sumit Parikh, Rob Cummins, Paul Mitchell, Robyn H Guymer
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | WILEY | Published : 2017
BACKGROUND: Late neovascular age-related macular degeneration (nvAMD) is very common and causes irreversible severe visual loss unless treated swiftly with vascular endothelial growth factor (VEGF) inhibitors. Although publicly subsidized access to treatment may be inequitable, which is why we assessed treatment provision across Australia. DESIGN: Secondary analysis of Australian data. PARTICIPANTS: All Pharmaceutical Benefits Scheme (including Repatriation PBS) beneficiaries. METHODS: Treatment and incidence data were obtained from Medicare Australia, the Royal Australian and New Zealand College of Ophthalmologists, Optometry Australia, the Blue Mountains Eye Study and the Australian Bureau..View full abstract
This study was supported by the MDFA, the Charles Viertel Charitable Foundation, the Lloyd and Kathleen Ansell Ophthalmology Foundation and the Mankiewicz-Zelkin Fellowship of the University of Melbourne to Dr Finger. CERA receives Operational Infrastructure Support from the Victorian Government. The MDFA receives funding from Novartis Australia, Bayer Australia and the NSW and Federal Governments. The funders had no role in designing, implementing, analysing or reporting of this study.